France / United States / Canada / Australia / United Kingdom / /
Event
FDA Phase / /
Facility
Lady Elgin Room Lord Elgin Hotel / /
IndustryTerm
healthcare professional / /
MedicalCondition
opioid drug dependence / respiratory depression / /
MedicalTreatment
drug therapies / Drug Therapy / /
Organization
Canadian Society of Addiction Medicine / Government of Canada / Government of Canada Web Standards / office of Controlled Substances / Bureau of Cardiology / Allergy & Neurological Sciences / Centre for Addiction and Mental Health / Therapeutic Products Directorate / Centre for Addiction and Mental Health Question / National Subutex7 Medical Advisory Board / A/Head Policy Section office of Controlled Substances Questions of Clarification / /
Person
Richard Arlen / Robert Peterson / Centre / Theresa Schopf / Meldon Kahan / Patrice LaRose / David Marsh / Siddika Mithani / C. Buprenorphine / Facilitator Carole Bouchard / P. LaRose / Buprenorphine Theresa Schopf / / /
Position
Product Manager / Medical Consultant / A/Director General / Drug Strategy / Director / VP / Regulatory Affairs / Drug Safety and Medical Services / Physician / A/Director General / addiction counsellor / A/Head Policy / Director General / /
Product
buprenorphine hydrochloride / Subutex / France / buprenorphine / /
Untitled Document This content was archived on June 24, 2013. Archived Content Information identified as archived on the Web is for reference, research or recordkeeping purposes. It